指南与共识中枢神经肿瘤放疗姑息放疗与转移瘤

术后脑转移瘤手术腔的立体定向放射外科:国际立体定向放射外科协会(ISRS)实践指南

Stereotactic Radiosurgery for Postoperative Metastatic Surgical Cavities: A Critical Review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2021-04-20

该指南由ISRS基于系统检索(截至2018年7月20日)的8项回顾性系列、1项2期前瞻性研究、3项随机对照试验和1项共识勾画论文制定,评估单次SRS与分次SRT用于术后脑转移瘤切除腔的疗效与毒性。随机数据显示单次SRS局部控制优于观察、认知结局优于全脑放疗(WBRT),但劣于WBRT的局部控制可能受SRS组保守处方剂量影响;回顾性研究显示局部控制率60.5%–91%(中位80.5%),ISRS推荐SRS作为符合条件的术后患者的一线治疗。

要点

  • ISRS推荐SRS作为符合条件的术后脑转移瘤患者的一线治疗。
  • SRS/SRT处方剂量与局部控制率相关,回顾性研究报告为60.5%–91%(中位80.5%)。
  • 分次SRT可能对大的肿瘤腔体积/直径及术前直径大于2.5 cm者局部控制更优。

核心结论

  • ISRS推荐SRS作为符合条件的术后脑转移瘤患者的一线治疗,因神经认知结局更优且不放弃WBRT无生存劣势。
  • 随机数据提示单次SRS局部控制优于观察、认知结局优于WBRT,但局部控制劣于WBRT,可能受SRS组保守处方剂量影响。
  • 回顾性研究显示单次SRS与分次SRT用于术后脑转移瘤均有较高的局部控制率。
  • 新兴数据提示分次SRT可能较大肿瘤腔体积/直径及术前直径大于2.5 cm者局部控制优于单次SRS。

研究设计与样本

  • 制定机构为国际立体定向放射外科协会(ISRS),采用Medline与Embase数据库并按PRISMA方法检索,检索截止2018年7月20日。
  • 纳入标准为仅含术后脑转移瘤且至少100例患者的前瞻性研究、共识指南和回顾性系列。
  • 最终纳入8项回顾性系列、1项2期前瞻性研究、3项随机对照试验和1项共识勾画论文。

主要发现

  • SRS/SRT处方剂量为30–50 Gy EQD210、50–70 Gy EQD25、70–90 Gy EQD22时,局部控制率为60.5%–91%(中位80.5%)。
  • 随机数据提示单次SRS较观察改善局部控制,较WBRT改善认知结局。
  • 术后SRS/SRT的毒性有限。
  • 随机数据提出切除腔SRS后局部控制劣于WBRT的担忧,可能由SRS组保守处方剂量等因素驱动。

关键数值与推荐

  • ISRS推荐SRS作为符合条件的术后患者的一线治疗。
  • 处方剂量30–50 Gy EQD210、50–70 Gy EQD25、70–90 Gy EQD22对应局部控制率60.5%–91%(中位80.5%)。
  • 分次SRT可能对大的肿瘤腔体积/直径及术前直径大于2.5 cm者较单次SRS局部控制更优。

临床怎么用

  • 对符合条件的术后脑转移瘤患者,可将SRS作为一线治疗选择,并权衡其神经认知优势与WBRT的局部控制比较。
  • 制定SRS/SRT处方剂量时需考虑剂量对局部控制的影响,避免因保守剂量导致局部控制下降。
  • 对大的肿瘤腔体积/直径或术前直径大于2.5 cm者,可考虑分次SRT以改善局部控制。

局限性

  • 随机数据中SRS组局部控制劣于WBRT,可能受保守处方剂量等因素影响,需谨慎解读。
  • 支持分次SRT优于单次SRS的数据为新兴数据,证据尚不成熟。
  • 纳入证据以回顾性系列为主,前瞻性随机证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this critical review is to summarize the literature specific to single-fraction stereotactic radiosurgery (SRS) and multiple-fraction stereotactic radiation therapy (SRT) for postoperative brain metastases resection cavities and to present practice recommendations on behalf of the ISRS. METHODS AND MATERIALS: The Medline and Embase databases were used to apply the Preferred Reporting Items for Systematic Reviews and Meta-Analyses approach to search for manuscripts reporting SRS/SRT outcomes for postoperative brain metastases tumor bed resection cavities with a search end date of July 20, 2018. Prospective studies, consensus guidelines, and retrospective series that included exclusively postoperative brain metastases and had at minimum 100 patients were considered eligible. RESULTS: The Embase search revealed 157 manuscripts, of which 77 were selected for full-text screening. PubMed yielded 55 manuscripts, of which 23 were selected for full text screening. We deemed 8 retrospective series, 1 phase 2 prospective study, 3 randomized controlled trials, and 1 consensus contouring paper appropriate for inclusion. The data suggest that SRS/SRT to surgical cavities with prescription doses of 30 to 50 Gy equivalent effective dose (EQD) 210, 50 to 70 Gy EQD25, and 70 to 90 EQD22 are associated with rates of local control ranging from 60.5% to 91% (median, 80.5%). Randomized data suggest improved local control with single-fraction SRS compared with observation and improved cognitive outcomes compared with whole-brain radiation therapy (WBRT). The toxicity of SRS/SRT in the postoperative setting was limited and is reviewed herein. CONCLUSIONS: Although randomized data raise concern for poorer local control after resection cavity SRS than WBRT, these findings may be driven by factors such as conservative prescription doses used in the SRS arm. Retrospective studies suggest high rates of local control after single-fraction SRS and hypofractionated SRT for postoperative brain metastases. With a superior neurocognitive profile and no survival disadvantage to withholding WBRT, the ISRS recommends SRS as first-line treatment for eligible postoperative patients. Emerging data suggest that fractionated SRT may provide superior local control compared with single-fraction SRS, in particular, for large tumor cavity volumes/diameters and potentially for patients with a preoperative diameter greater than 2.5 cm.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Redmond KJ, De Salles AAF, Fariselli L, et al. Stereotactic Radiosurgery for Postoperative Metastatic Surgical Cavities: A Critical Review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. Int J Radiat Oncol Biol Phys. 2021. PMID: 33891979. doi:10.1016/j.ijrobp.2021.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。